Edition:
United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

43.22USD
4:00pm BST
Change (% chg)

$-0.97 (-2.20%)
Prev Close
$44.19
Open
$44.13
Day's High
$44.63
Day's Low
$43.02
Volume
97,142
Avg. Vol
201,189
52-wk High
$60.98
52-wk Low
$36.19

Gotto, Antonio 

Dr. Antonio M. Gotto, Jr., M.D., Ph.D. is an independent Director of the Esperion Therapeutics Inc. He currently serves as Dean Emeritus and Medical Provost and as a member of the Board of Overseers of the Joan and Sanford I. Weill Medical College of Cornell University, and is currently a Vice President of and consultant to Cornell University. From January 1997 to December 2011, he served as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University and Provost for Medical Affairs of Cornell University. Previously, Dr. Gotto served as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research and Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital. Dr. Gotto currently serves as a member of the Institute of Medicine of the National Academy of Sciences and as a Fellow of the American Academy of Arts and Sciences. Dr. Gotto is also a past president of the International Atherosclerosis Society and a past president of the American Heart Association. Dr. Gotto holds a B.A. degree from Vanderbilt University, a D.Phil. degree in Biochemistry from Oxford University in England, where he was a Rhodes Scholar, and an M.D. degree from Vanderbilt University School of Medicine. He completed his residency training at Massachusetts General Hospital in Boston, Massachusetts. Dr. Gotto was a member of the board of directors of Aegerion Pharmaceuticals, Inc. until December 2, 2016, when it merged to form Novelion Therapeutics, Inc. (NASDAQ: NVLN).

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 343,846
Long-Term Incentive Plans, USD --
All Other, USD 42,817
Fiscal Year Total, USD 386,663

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --